Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Kalb, Suzanne R ^a   Lou, Jianlong ^b   Garcia Rodriguez, Consuelo ^b   Geren, Isin N ^b   Smith, Theresa J ^c   Moura, Hercules ^a   Marks, James D ^b   Smith, Leonard A ^c   Pirkle, James L ^a   Barr, John R ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A1; BOTULINUM TOXIN A2; BOTULINUM TOXIN A3; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ARTICLE; BOTULISM; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACTION; IN VITRO STUDY; INHIBITION KINETICS; MASS SPECTROMETRY; NONHUMAN; ANIMAL; CLASSIFICATION; CLOSTRIDIUM BOTULINUM TYPE A; DRUG ANTAGONISM; EVALUATION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; PATHOGENICITY; SEROTYPING;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BOTULINUM TOXIN TYPE A; BOTULISM; CLOSTRIDIUM BOTULINUM TYPE A; HUMANS; MICE; SEROTYPING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 65449127764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005355     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention, Botulism in the United States: 1899-1996. Handbook for Epidemiologists, Clinicians and Laboratory Workers. Atlanta, Georgia: Centers for Disease Control and Prevention, 1998.
2. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80(2): 717-766.
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8): 1059-1070.
4. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Letters 580: 2011-2014.
5. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596.
6. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Ann Rev Pharmacol Toxicol 44: 167-193.
7. Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, et al. (2005) Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 11(10): 1578-1583.
8. Boyer AE, Moura H, Woolfitt AR, Kalb SR, Pavlopoulos A, et al. (2005) From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal Chem 7: 3916-3924.
9. Kalb SR, Moura H, Boyer AE, McWilliams LG, Pirkle JL, et al. (2006) The Use of Endopep-MS for the detection of botulinum neurotoxins A, B, E, and F in serum and stool samples. Anal Biochem 351(1): 84-92.
10. Kalb SR, Goodnough MC, Malizio CJ, Pirkle JL, Barr JR (2005) Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics. Anal Chem 77(19): 6140-6146.
11. Gaunt PS, Kalb SR, Barr JR (2007) Detection of Botulinum Type E Toxin in channel catfish with visceral toxicosis syndrome using catfish bioassay and endopep mass spectrometry. J Vet Diagn Invest 19(4): 349-354.
12. Kalb SR, Smith TJ, Moura H, Hill K, Lou J, et al. (2008) The Use of Endopep-MS to detect multiple subtypes of botulinum neurotoxins A, B, E, and F. International Journal of Mass Spectrometry 278: 101-108.
13. Kautter DA, Solomon HM (1977) Collaborative study of a method for the detection of Clostridium botulinum and its toxins in foods. J Assoc Anal Chem 60(3): 541-545.
14. Cenci Di Bello I, Poulain B, Shone CC, Tauc L, Dolly JO (1994) Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes. Eur J Biochem 219: 161-169.
15. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, et al. (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25: 107-116.
16. Mah DC, Hu WG, Pon JK, Masri SA, Fulton RE, et al. (2003) Recombinant anti-botulinum neurotoxin A single-chain variable fragment antibody generated using a phage display system. Hybrid Hybridomics 22(5): 277-285.
17. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, et al. (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 99(17): 11346-11350.
18. Pless DD, Torres ER, Reinke EK, Bavari S (2001) High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 69: 570-574.
19. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, et al. (2005) Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 351: 158-169.
20. Shone C, Wilton-Smith P, Appleton N, Hambleton P, Modi N, et al. (1985) Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay. Appl Environ Microbiol 50: 63-67.
21. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, et al. (1997) Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infection Immunity 65: 3743-3752.
22. Amersdorfer P, Wong C, Smith T, Chen S, Desphande S, et al. (2002) Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20: 1640-1648.
23. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, et al. (2007) Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol 189(3): 818-832.
24. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, et al. (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73(9): 5450-5457.
25. Jensen MJ, Smith TJ, Ahmed SA (2003) Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41(6): 691-701.
26. Geren IN, Lou J, Garcia C, Conrad F, Fan F, et al. Human monoclonal antibodies to botulinum neurotoxin types A and B from immune yeast displayed antibody libraries. submitted to J Mol Biol.
27. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, et al. (2007) Fine and domain-level epitope mapping of botulinum neurotoxin type a neutralizing antibodies by yeast surface display. J Mol Biol 365: 196-210.
28. Lacy DB, Tepp W, Cohen AC, dasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10): 898-902.